Program for all days

Better Kidney Health
The Interconnected Kidney
Preserving Kidney Health
The Smart Kidney
Plenary Sessions
Pre-congress Courses
Spotlight Sessions
Special Sessions
Industry Symposia
Global Kidney Policy Forum
Welcome Reception
Topical Networking
Poster Sessions

28 March 2026

Time Session
3:45 p.m.
4:45 p.m.
HIT! High Impact Clinical Trials 1
KatherineTuttle Chair Katherine.Tuttle@providence.orgUnited States
  • Remodel Overview - Framework And Key Outcomes
    PetterBjornstad Speaker petter.m.bjornstad@cuanschutz.eduUnited States
  • Semaglutide Improves Kidney Outcomes Regardless Of SGLT2i Use In People With Chronic Kidney Disease And Type 2 Diabetes: Post-hoc Analysis The Remodel Trial
    DavidCherney Speaker david.cherney@uhn.on.caCanada
  • ACHIEVE
    MichaelWalsh Speaker lastwalsh1975@gmail.comCanada
  • B-cell Targeted Therapy for Idiopathic Nephrotic Syndrome: Results of the Phase III Global Multicenter Inshore Trial Evaluating Efficacy and Safety of Obinutuzumab vs Mycophenolate Mofetil
    JulienHogan Speaker julien.hogan2@aphp.frFrance
  • Q&A Session
Main Hall

29 March 2026

Time Session
9:25 a.m.
10:55 a.m.
HIT! High Impact Clinical Trials 2 - New Insights Into Ongoing Trials
AdeeraLevin Chair alevin@providencehealth.bc.caCanada
Andrea Viecelli Chair andrea.viecelli@usz.chSwitzerland
RobertoPecoits-Filho Chair roberto.pecoits@arborresearch.orgUnited States
  • ASPIRE (Aspirin in Dialysis PTS/ China): Large Pragmatic Trial
    XueqingYu Speaker yuxueqing@gdph.org.cnChina
  • RESOLVE (NA CONCENTRTION IN DIALYSIS POPULATIONS: GLOBAL): CLUSTER RANDOMIZED TRIAL
    MegJardine Speaker meg.jardine@sydney.edu.auAustralia
  • VOICE
    ShuchiAnand Speaker sanand2@stanford.eduUnited States
  • TEST PD
    JosephineChow Speaker Josephine.Chow@health.nsw.gov.auAustralia
  • Renal Life Cycle
    HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
  • Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-proven Primary Glomerular Diseases: Multi-center, Multi-arm and Multi-stage- the Story So Far
    Selvin Sundar RajMani Speaker selvinsr@gmail.comIndia
  • Q&A
Main Hall
2:10 p.m.
3:10 p.m.
HIT! High Impact Clinical Trials 3 - In IgA Nephropathy
Sydney Tang Chair scwtang@hku.hkHong Kong, China
  • Efficacy and Safety Results of Atrasentan in Patients With IgA Nephropathy on Sodium‚ äìglucose Co-transporter 2 Inhibitors: Phase II, Randomized, Placebo-controlled, Crossover Trial (Assist)
    HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
  • Efficacy and Safety of a Targeted-release Formulation of Budesonide (HR19042 Capsules) in Patients With Primary IgA Nephropathy: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2/3 Trial
    XiaobingYang Speaker yxb7829@163.comChina
  • Evaluating the Effect of Sparsentan vs Irbesartan on Urine Inflammatory and Profibrotic Biomarkers in the Phase 3 Protect Trial of Patients With Immunoglobulin a Nephropathy
  • Efficacy and Safety of Iptacopan in Patients With IgA Nephropathy (IgAN): Final 24-month Results From the Phase III Applause-IgAN Study
    VladoPerkovic Speaker vlado.perkovic@unsw.edu.auAustralia
  • Q&A
Main Hall

30 March 2026

Time Session
9:25 a.m.
10:55 a.m.
HIT! High Impact Clinical Trials 4
KeiFukami Chair fukami@med.kurume-u.ac.jpJapan
LizLightstone Chair l.lightstone@imperial.ac.ukUnited Kingdom
MasaomiNangaku Chair mnangaku@m.u-tokyo.ac.jpJapan
  • Effect of a 12-week Intradialytic Cycling Intervention on Hemodialysis-induced Myocardial Stunning: A Multi-centre Randomized Controlled Trial (Tickers_hd)
    ClaraBohm Speaker cbohm@sogh.mb.caCanada
  • Effect of Finerenone on Circulating Biomarkers: A Confidence Analysis
    MarioBerger Speaker mario.berger@bayer.comGermany
  • Effect of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-creatinine Ratio by Age and Sex in the Confidence Trial
    RajivAgarwal Speaker ragarwal@iu.eduUnited States
  • Estimated Glomerular Filtration Rate, Systolic Blood Pressure, and Urinary Albumin-to-creatinine Ratio — Unravelling the Interplay in Combination: Findings From the CONFIDENCE Trial
    RajivAgarwal Speaker ragarwal@iu.eduUnited States
  • Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients: A Prospective, Multicenter, Double Blind Randomized Controlled Trial
    Naya Huang Speaker huangnaya@163.comChina
Main Hall